Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus VenetoclaxNitin Jain, Lisa J Croner, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemiaAlessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Cancer Biomarkers : Section a of Disease Markers|July 24, 2012
Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemiaAlessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, et al.
Haematologica|March 15, 2006
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trialGiuseppe Cimino, Fabrizio Pane, Loredana Elia, et al.
Pageof 17